One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Reflections on the past
doi : 10.1016/S1470-2045(22)00069-9
Volume 23, Issue 3, March 2022, Page 317
Genetic risk of cancer: a tale of diversity from the Middle East
Khawla SAl-Kurayaa
Medical treatment for active breast cancer brain metastases
CarolineBailleuxaThomasBachelotb
Frontline chemotherapy-free induction for mantle cell lymphoma
UmbertoVitoloaMattiaNovoa
Importing oncology trials from China: a bridge over troubled waters?
HarpreetSinghaRichardPazdura
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
GabrieleAntonarelliabCarmineValenzaabErica LMayercdSibylleLoiblefgGiuseppeCuriglianoab
Progression-free survival: it is time for a new name
BishalGyawaliabcElizabethEisenhaueraMichelleTregeardChristopher MBoothabc
Retraction and republication—Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Code of practice needed for samples donated by trial participants
RobertColemanaArleneChanbCarlosBarrioscDavidCamerondLuisCostaeMitchDowsettfDavidHarrisongAnthonyHowellhiDenisLacombejMaireadMacKenziekMiguelMartinlStuartMcIntoshmAdrienneMorgankMartinePiccartnTanjaSpanico
Code of practice needed for samples donated by trial participants – Sponsor's reply
DougWarneraAnthonyGlennaneaByeongYoonaHossamSaada
Climate crisis and cancer: perspectives from the hardest hit
Michelle Ann BEalaaJanine Patricia GRobredobEdward ChristopherDeecVivianLindAlfredo Mahar Francisco ALagmaye
ROAR trial: which treatment is effective after progression?
OsmanSütcüoğluaKadriye BirYücelaAytuğÜneraOzanYaziciaNuriyeÖzdemira
ROAR trial: which treatment is effective after progression? – Authors' reply
Patrick YWenaPaulBurgessbPalanichamyIlankumarancVivekSubbiahd
Survivorship after neoadjuvant chemotherapy
JinZhangaChaoyangLiangaWenquanNiub
Survivorship after neoadjuvant chemotherapy – Authors' reply
ChristinaYauaMarieOsdoitbLaura JEssermanaW FraserSymmansc
Post-protocol therapy and informative censoring in the CANDOR study
TomerMeirsonaGalMarkelabVinayPrasadcAaron MGoodmandGhulam RehmanMohyuddine
Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply
Saad ZUsmaniaChuangLibMihaelaObrejabMeletiosDimopoulosc
HLA-A*03 and response to immune checkpoint blockade in patients with cancer
Leonidas NDiamantopoulosaLeonard JApplemanb
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting
NayshaBecerra-ChaucaacWendyNieto-GutierrezbcAlvaroTaype-Rondanbc
Malaysia to ban tobacco sales to people born after 2005
ManjulikaDas
New agreement to strengthen paediatric cancer treatment in Libya
ManjulikaDas
NICE withdraws quality standard on colorectal cancer treatment after “lack of consensus�
EmmaWilkinson
President Biden outlines plans for Cancer Moonshot 2.0
ElizabethGourd
Gender disparities in access to paediatric cancer care in India
ManjulikaDas
US Congress considers new health-care bill for burn pit-exposed veterans
BryantFurlow
IAEA and Brazilian Navy to provide new arsenal to fight breast cancer: mammography on a ship
MarciaTriunfol
Bangladesh decentralises cancer care services to expand access to care
ManjulikaDas
Yale Precision Medicine Tumor Board: reawakening the guardian of the genome
Michael JGranta†Karin EFinbergb†ZentaWaltherbStacey MSteinaJillLacyaJoseph PEderaSarah BGoldberga
Still Max: Max Dean asks how we can fix ourselves
CatherineLucas
Sentinel nodes and breast cancer: an old story
EmmanuelDrouinaJean-MarcClassebcPatrickHautecoeura
Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study
MohamadSaadPhDa*YounesMokrabPhDb*NajeebHalabiPhDe*JingxuanShanPhDefRozaimiRazaliPhDbKhalidKunjiMScaNajeebSyedMSccRamziTemanniPhDhMuruganSubramanianPhDegMicheleCeccarelliPhDijQatar Genome Programme Research Consortium†ProfArashRafii TabriziMDefDavideBedognettiMDdProfLotfiChouchaneDScefg
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
MinYanMDaQuchangOuyangMDbTaoSunMDcLiminNiuMDaJinYangMDdLiLiMDeYuhuaSongMDfChunfangHaoMDgZhanhongChenMMhArmandoOrlandiMDiNaohiroIshiiMDkKazuakiTakabeMDlGianlucaFranceschiniMDjFrancescoRicciMDmClaireVerschraegenMDnZhenzhenLiuMDaMengweiZhangMMaHuiminLvMMa…GuifangZhangMBo
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
ProfMatthew RSmithMDabProfHoward IScherMDcShahneenSandhuMDdEleniEfstathiouMDeProfPrimo NLaraJrMDfProfEvan YYuMDgProfDaniel JGeorgeMDhProfKim NChiMDiProfFredSaadMDjOlofStåhlMDkDavidOlmosMDlDaniel CDanilaMDcGary EMasonMDmByron MEspinaBSnXinZhaoPhDoKaren AUrtishakPhDmPeterFrancisMDpAngelaLopez-GitlitzMDn…HelenMoon
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
ProfDean AFennellFRCPaAmyKingMScbSeidMohammedMSccAlastairGreystokeFRCPdSarahAnthonyBSccCharlottePoilePhDaNadaNusratMDaMollyScotlandRNbVinaBhundiaBScbAmyBransonBSccCassandraBrookesMSccLizDarlisonMScbAlan GDawsonMResaAartiGabaMScaMargaretHutkaMDbProfBrunoMorganFRCRbAmritaBajajFRCRbCathyRichardsFRCPathb…AnneThomas
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
AntoineThiery-VuilleminMDaProfJohannde BonoMDbProfMahaHussainMDcGuilhemRoubaudMDdGiuseppeProcopioMDeNealShoreMDfProfKarimFizaziMDgGabrieldos AnjosMDhGwenaelleGravisMDiJae YoungJoungMDjNobuakiMatsubaraMDkDanielCastellanoMDlArnoldDegboeMDmChrisGrestyPhDnJinyuKangMDmAllisonAllenPhDmChristianPoehleinMDoProfFredSaadMDp
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
ProfMichael LWangMDaPreeteshJainMDaShuangtaoZhaoPhDcHun JuLeeMDaLorettaNastoupilMDaProfLuisFayadMDaChi YoungOkMDdRashmiKanagal-ShamannaMDdHolly AHillMPHaYixinYaoPhDaProfFredrick BHagemeisterMDaJason RWestinMDaProfNathanFowlerMDaProfFelipeSamaniegoMDaRaphaelSteinerMDaRanjitNairMDaProfSwaminathan PIyerMDaLucyNavsariaMPHa…LinghuaWangPhDcj
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
ProfPaul GRichardsonMDaProfAurorePerrotMDbProfJesusSan-MiguelMDcProfMeralBeksacMDdProfIvanSpickaMDeProfXavierLeleuMDfFredrikSchjesvoldMDgProfPhilippeMoreauMDhProfMeletios ADimopoulosMDiJeffrey Shang-YiHuangMDjJiriMinarikMDkProfMicheleCavoMDlProfH MilesPrinceMDmLaureMalingeMScnFranckDubinPharmDnHelgivan de VeldeMDnProfKenneth CAndersonMDa
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study
Alistair D RGreyFRCS [Urol]adhiRebeccaScottRNaBinaShahBScbPeterAcherFRCS [Urol]fSidathLiyanageFRCRgMenelaosPavlouPhDcProfRumanaOmarPhDcProfFrankChinegwundohFRCS [Urol]hPrasadPatkiFRCS [Urol]hTaimur TShahFRCS [Urol]iSamiHamidMRCSjManeeshGheiFRCS [Urol]jKayleighGilbertBScjDianeCampbellRNhChrisBrew-GravesMScbNimalanArumainayagamFRCS [Urol]kAlexChapmanFRCRlLauraMcLeavyMScm…ProfHashim UAhmedFRCS [Urol]im
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
XiaofeiZhuMDa†YangsenCaoMDa†WenyuLiuMDa†XiaopingJuMDa†XianzhiZhaoMDaLingongJiangMDaYushengYeMDaProfGangJinMDbProfHuojunZhangMDa
A comprehensive framework for early-onset colorectal cancer research
ProfCathyEngMDafAlexandre AJácomeMDgRajivAgarwalMDafMuhammad HashimHayatMDbMariana XByndlossPhDcAndreana NHolowatyjPhDdfChristinaBaileyMDeChristopher HLieuMDh
Toxicity and efficacy of chronomodulated chemotherapy: a systematic review
Markella IPrinteziBSca†Aoife BKilgallenMScab†Marinde J GBondMDcUrškaŠtiblerBScabMarritPutkerPhDeArco JTeskeMDaMaarten JCramerMDaProfCornelis J APuntMDcProfJoost P GSluijterPhDabProfAlwin D RHuitemaPhDdfgProfAnne MMayPhDcLinda Wvan LaakeMDab
Essential medicines list in national cancer control plans: a secondary analysis from a global study
EvangeliaRazisMDaMarieKassapianMScbCharitiniAndriakopoulouMScbProfYehoda MMarteiMDcShalini JayasekarZurnMScdNazikHammadMDeYannickRomeroPhDdProfUraniaDafniScDbfAndré MIlbawiMDgDarioTrapaniMDh
Granulocyte colony-stimulating factor-associated aortitis
ToshiakiTakahashiMDaKazumasaYamamotoMDaTakeshiYamaguchiMDaYujiMiuraMDaRikaKizawaMDa
